GlassScriptPhysician profile
Nancy R Feldman
NPI 1538184700
$43,598.07
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $1,164 · 2021: $373.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $41,938.71 | 2019 | |
| Athenex Pharmaceutical Division, LLC | $1,100.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $350.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.60 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $37.84 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $35.07 | 2019-2020 | |
| Amgen INC. | $28.75 | 2020 | |
| Pfizer INC. | $28.11 | 2019 | |
| Celgene Corporation | $22.93 | 2021 | |
| Janssen Biotech, INC. | $15.06 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.